Clinical Trial

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, open-label, randomized, controlled, multi-center clinical trial. The aim of this study is to investigate the efficacy and safety of Telitacicept in adults with early diffuse cutaneous systemic sclerosis (dcSSc), with Mycophenolate Mofetil (MMF) administered as a background treatment.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT06375005
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Diffuse Cutaneous Systemic Sclerosis
Enrollment 38 participants
Start Date 2025-01-06
Primary Completion 2027-01-06 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-11